Molecular Partners AG

NASDAQ:MOLN

Biotechnology

Healthcare
$2.67 +0.77%

+$0.03 today

Market cap
$100.28M
Beta
0.71
P/E (TTM)
-2.0
EPS (TTM)
-$1.55
52W Low $3.41High $5.36

Volume 0.00M

Average 0.00M

MOLN Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Molecular Partners AGNASDAQ: MOLN

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -CHF 15.57M, compared with CHF 17.5M a year earlier. Trailing-twelve-month net change in cash was -CHF 41.33M. Over 3 fiscal years it compounded at +5.2% a year.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -CHF 15.57M or moves back toward the trailing-twelve-month quarterly average of -CHF 10.33M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 15.57M+12.0% QoQ
Last fiscal yearDec 2025
CHF 18.78M+646.7% YoY
LTMMar 2026
-CHF 41.33M-462.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-189.0%——
1 year+646.7%——
3-year CAGR+5.2%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

CHF · from the cash flow

Latest · FY2025
18.78M CHF
Year-over-year change
+646.7%

Net Change in Cash vs competitors

How MOLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -462.5% is the lowest of 9, against a peer median of -92.8%.
  • Over three fiscal years its annual growth of +5.2% compares with a peer median of -43.4%.
MOLN Competitors
Net Change in Cash for MOLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026CHF 41.33M CHF-462.5%+5.2%—
ALECAlector, Inc.LTM Mar 2026$38.99M USD+212.8%—211.7%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$26.23M USD-25.0%—1470.4%
NKTXNkarta, Inc.LTM Mar 2026$25.24M USD-87.2%——
CRDFCardiff Oncology, Inc.LTM Mar 2026$15.55M USD-386.0%—2962.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.48M USD+35.0%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$4.08M USD-162.5%-47.7%—
PEPGPepGen Inc.LTM Mar 2026$1.48M USD-98.4%-39.0%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$767K USD-123.7%—24.2%
Peer median (excluding MOLN) —-92.8%-43.4%841.1%

Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(63.79M)117.85M(61.98M)(54.04M)(61.65M)
Depreciation & Amortization2.57M2.39M2.42M2.37M2.14M
Deferred Income Tax2K002K2K
Stock-Based Compensation4.09M5.09M5.21M4.11M4.42M
Change in Working Capital(34.67M)(6.01M)(6.01M)(3.8M)1.16M
Accounts Receivables(23.37M)25.26M(933K)(347K)463.2K
Inventory21.72M(19.93M)000
Accounts Payables1.66M(5.34M)(812K)524K62.08K
Other Working Capital(34.67M)(6.01M)(4.27M)(3.97M)630.33K
Other Non-Cash Items848K(753K)1.36M(7.88M)2.67M
Operating Cash Flow(90.95M)118.57M(59.01M)(59.25M)(51.26M)
Capital Expenditures(1.31M)(1.42M)(575K)(723K)(714K)
Acquisitions (Net)374K0000
Purchases of Investments(88.88M)(299.42M)(277.83M)(240.05M)(66.28M)
Sales of Investments67.88M199.22M319.44M277.02M137.81M
Other Investing Activities(304K)494K3.83M4.22M1.73M
Investing Cash Flow(22.24M)(101.12M)44.64M40.49M72.55M
Debt Repayment(1.18M)(1.19M)(1.2M)(1.21M)(1.21M)
Common Stock Issued51.49M250K31K17.34M63K
Common Stock Repurchased0(631K)000
Dividends Paid00000
Other Financing Activities267K250K31K(1.7M)0
Financing Cash Flow50.58M(1.57M)(1.17M)14.43M(1.15M)
Effect of Forex Changes701K258K(5.1M)894K(1.36M)
Net Change in Cash(61.91M)16.13M(20.64M)(3.44M)18.78M
Free Cash Flow(92.26M)117.15M(59.81M)(59.97M)(51.97M)

Molecular Partners AG

NASDAQ:MOLN

Intrinsic Alpha fair value

Locked

Current Price

$2.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.